Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Ann Hepatol ; 18(6): 833-840, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31558418

RESUMEN

INTRODUCTION AND OBJECTIVES: A crucial issue when appraising the performance of non-invasive markers is the limitations of the reference standard they are compared to. Digital image analysis (DIA) was suggested as a reproducible approach expressing fibrosis numerically as a proportionate area (PA) (%). We aimed to evaluate ELF test with direct reference to PA (%), thereby explore the improvement in accuracy to discriminate significant fibrosis which may actually have been underestimated by categorical pathological staging. MATERIALS AND METHODS: PA (%) data were obtained by DIA of trichrome-stained liver biopsies of 52 chronic hepatitis patients. Paired serum samples of patients and additional 36 controls were performed to measure ELF test. Diagnostic performance characteristics of ELF test was derived in predicting significant fibrosis in the patient cohort, and also, in distinguishing healthy controls from patients with significant fibrosis. RESULTS: We found an AUROC value of 0.73 for ELF to predict significant fibrosis as assessed by DIA and a lower AUROC value of 0.66 when assessed by conventional pathology. Importantly, ELF test provided considerably high diagnostic accuracy to discriminate healthy controls from patients with significant fibrosis defined by Ishak F≥2 and TPA≥5% (AUROCs 0.93 and 0.94, respectively) with optimal ELF cut-off point of 8.4 for both. CONCLUSIONS: Digital quantification could represent a better reference standard than conventional pathology allowing a better discriminatory capability for ELF test. ELF test provided high diagnostic accuracy to discriminate healthy controls from patients with significant fibrosis suggesting a role as a screening strategy in the community setting.


Asunto(s)
Ácido Hialurónico/sangre , Procesamiento de Imagen Asistido por Computador , Cirrosis Hepática/diagnóstico , Hígado/patología , Fragmentos de Péptidos/sangre , Procolágeno/sangre , Inhibidor Tisular de Metaloproteinasa-1/sangre , Adolescente , Adulto , Anciano , Área Bajo la Curva , Estudios de Casos y Controles , Femenino , Humanos , Cirrosis Hepática/sangre , Cirrosis Hepática/patología , Masculino , Persona de Mediana Edad , Curva ROC , Índice de Severidad de la Enfermedad , Adulto Joven
2.
Turk J Gastroenterol ; 28(Suppl 2): 90-93, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-29303105

RESUMEN

The present guideline updates the Turkish recommendations for the screening, diagnosis and management of Hepatitis C virus (HCV) infection prepared by the Turkish Association for the Study of the Liver (TASL) and Viral Hepatitis Society (VHS). The aim of this guidance was to provide updates recommendations to physicians, who are interested in HCV care on the optimal screening, diagnosis and pre-treatment management for patients with HCV infection in Turkey. These recommendations, produced by panel experts, were aimed to addresses the management issues ranging from diagnosis and linkage to care, to the optimal treatment regimen in patients with HCV infection. Recommendations are based on evidence and opinions of more than 70% of the panelists. This guidance is supported by the memberships of two societies and not by pharmaceutical companies. This guidance will be updated frequently as new data become available.


Asunto(s)
Manejo de la Enfermedad , Hepatitis C , Antivirales/normas , Antivirales/uso terapéutico , Hepacivirus , Humanos , Cirrosis Hepática/virología , Pruebas de Función Hepática/normas , Turquía
3.
J Gastroenterol Hepatol ; 18(4): 437-44, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12653893

RESUMEN

BACKGROUND AND AIM: To evaluate the possible antifibrotic effects of two drugs, pentoxifylline (PTX) and interferon (IFN)-alpha as well as their combination, on a bile-duct-ligated rat hepatic fibrosis model. METHODS: Bile ducts of 34 female Wistar rats were ligated, and 24 bile ducts were sham operated. Bile-duct-ligated rats were divided into four groups, in which either sterile saline, IFN-alpha (100 000 IU/3 days a week), PTX (50 mg/kg/day) or IFN-alpha + PTX were administered. Sham-operated rats were treated at the same doses. On the 28th day, rats were decapitated to obtain blood for the measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) and bilirubins. Serum prolidase was assayed at the beginning and at the end of the study by the modified Chinard's colorimetric method. Liver prolidase was assayed after tissue homogenization. Liver collagen content was determined by the dye elution method described by Lopez de Leon. Morphometric-densitometric measurements of hepatic fibrosis were quantified by computerized image analysis. RESULTS: The AST, ALT, ALP, GGT and bilirubins, liver prolidase enzyme activity, collagen content and hepatic collagen surface density were found to be increased in bile-duct-ligated rats on day 28. There was no statistically significant recovery or even a change in collagen turnover rate in rats treated with alternate regimens applied in the study (P > 0.05). CONCLUSION: Pentoxifylline, IFN-alpha and their combination have no beneficial effect on experimental fibrosis induced by biliary obstruction.


Asunto(s)
Colestasis/tratamiento farmacológico , Colestasis/enzimología , Colágeno/análisis , Dipeptidasas/sangre , Factores Inmunológicos/uso terapéutico , Interferón-alfa/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/enzimología , Pentoxifilina/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Animales , Colestasis/patología , Modelos Animales de Enfermedad , Quimioterapia Combinada , Femenino , Factores Inmunológicos/administración & dosificación , Interferón-alfa/administración & dosificación , Cirrosis Hepática/patología , Pentoxifilina/administración & dosificación , Inhibidores de Agregación Plaquetaria/administración & dosificación , Ratas , Ratas Wistar , Insuficiencia del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA